As artificial intelligence technology rapidly advances, its deployment within the medical sector presents substantial ethical challenges. Consequently, it becomes crucial to create a standardized, transparent, and secure framework for processing medical data. This includes setting the ethical boundaries for medical artificial intelligence and safeguarding both patient rights and data integrity. This consensus governs every facet of medical data handling through artificial intelligence, encompassing data gathering, processing, storage, transmission, utilization, and sharing. Its purpose is to ensure the management of medical data adheres to ethical standards and legal requirements, while safeguarding patient privacy and data security. Concurrently, the principles of compliance with the law, patient privacy respect, patient interest protection, and safety and reliability are underscored. Key issues such as informed consent, data usage, intellectual property protection, conflict of interest, and benefit sharing are examined in depth. The enactment of this expert consensus is intended to foster the profound integration and sustainable advancement of artificial intelligence within the medical domain, while simultaneously ensuring that artificial intelligence adheres strictly to the relevant ethical norms and legal frameworks during the processing of medical data.
Artificial Intelligence/legislation & jurisprudence* ; Humans ; Consensus ; Computer Security/standards* ; Confidentiality/ethics* ; Informed Consent/ethics*

OBJECTIVE: To investigate the prognostic factors of early stage adenocarcinoma of uterine cervix.METHODS: Totally 176 cases of early stage adenocarcinoma of uterine cervix who were admitted to Liaoning Cancer Hospital from January 2003 to May 2013 were analyzed retrospectively.RESULTS: The median age of 176 cases was 45(20-73),The 5-year overall survival rate was 81%. The 5-year tumor-free survival rate was 74.0%. The median survival time was 85 months.In univariate analysis,prognostic factors of patients with early cervical adenocarcinoma were clinical stage and lymph node metastasis.The five-year survival rate of ⅠB1,ⅠB2 and ⅡA1 was 86.0%,74.0% and 66.0%,and there were statistical differences(P<0.05).Compared with patients of ⅠB stage,the risk of death inⅡA1 patients was significantly increased(HR=2.92,95%CI 1.37-6.21).Totally 151 cases were pathologically proved with negative lymph node metastasis and 25 cases positive. The 5-year survival rates of them were 87.0% and 32.0% respectively and there were statistical differences between them(P<0.05).Multivariate analysis showed that only lymph node metastasis was an independent factor for survival(HR=5.86,95%CI 2.85-12.05).CONCLUSION: The 5-year survival rate of early-stage adenocarcinoma of uterine cervix is high;lymphnode metastasis is an important prognostic factor of early stage adenocarcinoma of uterine cervix.